SleepX (by OTC: APYP) has developed smart wearable monitoring devices for treating sleep apnea and snoring.
The mission of SleepX, a division of AppYea (OTC: APYP), is to develop precise and smart wearable monitoring solutions to treat sleep apnea and snoring, and essentially enhance the quality of life.
For tracking, analyzing, and diagnosing vital signs and other physical parameters during sleep time, the company’s solutions are based on its proprietary IP portfolio of AI and sensing technologies, providing incredibly high accuracy and resistance at a reasonable price.
The main product of SleepX is DreamIT, a patented wristband that interacts with a smartphone app to subtly vibrate with each breathing interruption, causing a shift from deep to lighter sleep and teaching the brain to breathe correctly. With the help of the company’s machine learning technology, the app analyses a user’s sleep and breathing patterns to adjust the treatment and suggest enhancements. Users will have access to crucial statistics about their sleeping habits via the app to track and detect anomalies over time, in addition to reducing snoring and improving sleep quality.
DreamIT is being developed in collaboration with the Biomedical department of the Ben Gurion University of the Negev and is patent protected in the US, EU, and Israel.
The Global Anti-Snoring Treatment Market is anticipated to grow to USD 8.6 billion by 2028, at a CAGR of 9.07 percent between 2021 and 2028, according to market intelligence firm Fior Markets. According to a recent report by Grand View resources Research, Inc., the size of the global market for sleep apnea devices was estimated at USD 3.7 billion in 2020 and is anticipated to grow at a 6.2 percent CAGR from 2021 to 2028 reaching USD 6.1 billion by 2028.
And with SleepX developing such smart wearable monitoring solutions, it is a potentially great company for investors.
For more details, visit https://www.sleepxclear.com